AAV-mediated gene therapy / DegenRx 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    News 
  • ||||||||||  AAV-mediated gene therapy / DegenRx
    [VIRTUAL] AAV mediated gene therapy as local treatment modality directed against amyloid beta oligomers in the brain using a high affinity, high specificity antibody (AAIC 2020) -  Aug 2, 2020 - Abstract #ODO3-14-04; Author: Bas Blits; Titia Gebuis; Yvonne Gouwenberg; Hans Preusting; Guus Scheefhals; August B. Smit; Rolinka van der Loo; Ronald E. van Kesteren; Presentation Time: July 29, 2020; 00:45-01:00   
    Recombinant AAV-5 vector encoding for the antibody is tested positive in vitro and in vivo, suggesting that the antibody can be expressed and secreted in the brain to target AB oligomers at the site where it is needed. Future studies should reveal whether native AB oligomers are also recognized and efficiently neutralized in an appropriate mouse model of AD resulting in enhanced cognitive performance.
  • ||||||||||  AAV-mediated gene therapy / DegenRx
    [VIRTUAL] AAV mediated gene therapy as local treatment modality directed against amyloid beta oligomers in the brain using a high affinity, high specificity antibody (AAIC 2020) -  Aug 2, 2020 - Abstract #SCR3-06-04; Author: Bas Blits; Titia Gebuis; Yvonne Gouwenberg; Hans Preusting; Guus Scheefhals; August B. Smit; Rolinka van der Loo; Ronald E. van Kesteren; Presentation Time: July 29, 2020; 08:45-09:00   
    Recombinant AAV-5 vector encoding for the antibody is tested positive in vitro and in vivo, suggesting that the antibody can be expressed and secreted in the brain to target AB oligomers at the site where it is needed. Future studies should reveal whether native AB oligomers are also recognized and efficiently neutralized in an appropriate mouse model of AD resulting in enhanced cognitive performance.